2016 - Fibrosis/Cirrhosis/Liver Cancer/Transplants
What is liver fibrosis?
Liver fibrosis is the scarring process that represents the liver’s response to injury. In the same way as skin
and other organs heal wounds through deposition of collagen and other matrix constituents so the liver repairs injury through the deposition of new collagen.
Over time this process can result in cirrhosis of the liver, in which the architectural organization of the functional units of the liver becomes so disrupted that blood flow through the liver and liver function become disrupted.
Once cirrhosis has developed, the serious complications of liver disease may occur, including portal hypertension, liver failure and liver cancer.
The risk of liver cancer is greatly increased once cirrhosis develops, and cirrhosis should be considered to be a pre-malignant condition. Cirrhosis and liver cancer are now among the top ten causes of death worldwide, and in many developed countries liver disease is now one of the top 5 causes of death in middle-age.
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir
ProMetic Presents Positive Results for PBI-4050 in Liver Fibrosis
LAVAL, QUEBEC, Nov 04, 2013 - ProMetic Life Sciences Inc. presented new preclinical data at the 2013 annual meeting of the American Association for the Study of Liver Diseases (AASLD) held in Washington on November 2-4 supporting the claims that PBI-4050 anti-fibrotic activity could also be used to address various liver conditions such as nonalcoholic steatohepatitis ("NASH"), a condition affecting 2% to 5% of Americans.
PBI-4050's favorable effect in reducing the progression of fibrosis in liver was demonstrated in two different "gold-standard" animal models. The first is a diabetic mouse model in which the animals develop liver steatosis. Similar to what is observed in humans, the untreated animals accumulate fat in the liver causing inflammation and leading to permanent damage and scarring, and reducing the ability for the liver to function properly. Diabetic mice treated with PBI-4050 had a significant reduction of liver lesions and steatosis measured by histology as well as a significant reduction in key biomarkers such as including TGFbeta-1, Collagen 1, MMP2 and TIMP-1.
In a second model, the liver fibrosis is induced by chronic administration of carbon tetrachloride (CCL4), a chemical which at high chronic dose, causes irreversible damage to the liver and the kidney. Again animals treated with PBI-4050 displayed a significant reduction of liver lesions as evidenced by histology and relevant biomarkers.
"These results clearly indicates that PBI-4050 anti-fibrotic activity is at the core of the fibrosis regulation pathway affecting multiple organs and tissues", stated Dr. Lyne Gagnon, Head of Biology & Immunology at ProMetic.
Dr. John Moran, a member of ProMetic's Board of Directors stated "Since patients with diabetes are more likely to develop complications affecting the kidneys and liver, the positive effects observed with PBI-4050 in multiple challenging animal models bodes well for its potential use in this patient population."
The presentation at the AASLD annual conference is available on the ProMetic website: http://www.prometic.com/en/therapeutics/conferences.php.
More on NASH
Nonalcoholic steatohepatitis or NASH is a common, often "silent" liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH affects 2 to 5 percent of Americans
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.
Estrogen protects women with NASH from severe liver fibrosis
Newly Approved Ultrasound Device Eliminates Risks and Pain of Liver Biopsy
October 7 2013
Telaprevir-based triple therapy potent for chronic HCV with advanced fibrosis
Diabetes Mellitus and Advanced Liver Fibrosis Are Risk Factors for Severe Anemia During Telaprevir-based Triple Therapy
Liver fibrosis linked to immune activation in HIV/HCV co-infected women
Andrea Kovacs from the Keck School of Medicine in Los Angeles presented findings from an analysis looking at associations between HIV and hepatitis C status, liver fibrosis biomarkers and immune activation.
Can Diet And Exercise Improve Fibrosis?
Moderate exercise is recommended for all persons with hepatitis C who did not experience advanced cirrhosis or other metabolic complications. In the present study, changes in food intake and the increase......
Dr. Joe Galati - Watch: Hepatitis C Diet and Exercise
It is now well known that obese individuals with hepatitis C have a higher chance of developing fibrosis, scarring, and cirrhosis of the liver. Diabetes, a fatty liver, and elevated levels of insulin also contribute to a greater chance of scarring and cirrhosis.
Aug 21 2013
Galectin Targets Silent Epidemic In Liver Fibrosis
Fatty liver disease, or the accumulation of fat in liver cells, is a "silent epidemic," says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics. In an interview with BioTuesdays.com, he says multiple liver diseases lead to
fibrosis, and end-stage fibrosis, or cirrhosis, leads to liver failure, medical complications and death. "With fatty liver disease, the most common liver disease, there are very few symptoms until patients reach late-stage disease, with advanced fibrosis and then cirrhosis."
Aug 19 2013
Liver Fibrosis Staging in Patients With Chronic HCV
Non-invasive fibrosis markers can distinguish between liver fibrosis stages in lieu of liver biopsy or imaging
Aug 16 2013
Histopathology of hepatitis C liver disease for determining hepatocellular carcinoma risk factors
To evaluate the histopathological findings of hepatitis C liver disease to determine risk factors for the development of hepatocellular carcinoma (HCC), we studied 232 patients, who underwent liver biopsy, with sustained virological response after interferon therapy. We investigated in detail the histopathological findings, and analyzed the findings to determine the risk factors. Consequently, atypical hepatocytes among irregular regeneration of hepatocytes may be an important risk factor for HCC development, along with progression of liver fibrosis.
Aug 12 2013
Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis
Aug 2 2013
Association of Visceral Obesity with High Viral Load and Histological Findings in Elderly Patients
with Genotype 1 Chronic Hepatitis C
...visceral obesity was found to be associated with high viral load, steatosis , and age-dependent fibrosis progression in patients with genotype 1 chronic hepatitis C.....
Download Full Text PDF [222K]
Effects of metabolic syndrome on fibrosis in chronic viral hepatitis
Various studies have already reported the association between liver fibrosis and metabolic syndrome in nonalcoholic fatty liver disease (NAFLD) and found that the components of metabolic syndrome are independent risk factors of liver
There are relatively less data on chronic viral hepatitis, however. With regards to chronic hepatitis C (CHC), studies
have reported that type 2 DM and other components of metabolic syndrome negatively affects the efficiency
of antiviral treatments. According to previous report, the prevalence of diabetes and metabolic syndrome were
raised in CHC patients, with accelerated progression of liver fibrosis. There are even less information regarding chronic
hepatitis B (CHB) than CHC. Only a few preliminary data suggested association between the components of metabolic syndrome—obesity, diabetes, hypertension, and hyperlipidemia—and liver fibrosis in CHB.
The aim of this study was to determine the association between metabolic syndrome and liver fibrosis in CHB and CHC.....
Original Article- Full Text Available Here
CDC- Hepatitis C Online Course
Hepatitis C patients taking part in the activity are given an opportunity to learn more about the progression of HCV,
the evaluation and prognosis of patients with cirrhosis and noninvasive tests for diagnosing and assessing liver
fibrosis. Other topics in the online course include a video presentation explaining "Extrahepatic Conditions Related to Hepatitis C Virus (HCV)" which may affect small vessels, skin, kidneys, salivary gland, eyes, thyroid, and immunologic system. This interactive course is offered in a text, video and slide presentation format.
Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
Vitamin D Levels and Liver Fibrosis Severity in Hepatitis C
In this complex and interesting interplay between liver and metabolic factors,
growing evidence also suggest a role of vitamin D status on liver disease
severity in patients with chronic hepatitis C.
Blood Tests OK for Fibrosis Dx in Hep C
Several blood tests can identify fibrosis in HCV
Radiologic Assessment of Liver Fibrosis – Present and Future
A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
Antiretrovirals Linked to Liver Fibrosis
EASL: Liver Imaging Tests Vie to Replace Biopsy
Sunshine Hormone, Vitamin D, May Offer Hope for Treating Liver Fibrosis
FDA Approves FibroScan for Noninvasive Liver Diagnosis
A ‘Killer’ of a Reason to Treat Hepatitis C
Dr. David Johnson stresses the importance of treating patients with hepatitis C and advanced hepatic fibrosis, given that those with sustained treatment response have a lower all-cause mortality rate.
Serum Bile Acid Levels as a Predictor for the Severity of Liver Fibrosis in Patients
With Chronic Hepatitis C
Although liver biopsy is considered the 'gold standard' for evaluating the presence and the
degree of liver fibrosis, concerns regarding its safety and the possibility
of sampling errors have led to the development of several noninvasive tools
that can predict the severity of liver fibrosis with a high degree of accuracy
Noninvasive Estimation of Fibrosis Progression Overtime Using the FIB-4 Index in Chronic Hepatitis C
Jan 9 2013
Researchers Foresee New Treatments and Diagnostics for Deadly Fibrotic Diseases of the Lung, Liver, and Kidney
Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study.
Patients with HCV and F1 and F2 fibrosis: treat now or wait?
Future polymerase inhibitors – The argument to wait. The only nucleoside polymerase inhibitor which has advanced to phase 3 clinical trials is subosfovir (GS-7977). In a phase 2 clinical trial, 177 patients with HCV genotypes 1, 4 or 6 were treated with
subosfovir, PEG-IFN/RBV for either 12 or 24 weeks...
Hepatitis C infection and presence of advanced fibrosis: Wait or treat? Why wait? There is no time to lose, is there?
Full Text - Magnetic Resonance Elastography for Staging Liver Fibrosis in Chronic Hepatitis C